Is ruxolitinib approved for GVHD?
Yes, ruxolitinib (Jakafi) is FDA-approved for treating steroid-refractory acute graft-versus-host disease (GVHD) in adults and patients 12 years and older after failure of one or more systemic therapies. Approval came in 2019 based on the phase 3 REACH3 trial, where it reduced mortality risk and improved response rates compared to best available therapy.[1][2]
How does ruxolitinib work in GVHD?
Ruxolitinib inhibits JAK1 and JAK2 enzymes, blocking inflammatory signaling pathways like IL-6 and IFN-gamma that drive GVHD. In GVHD, donor immune cells attack host tissues post-transplant; ruxolitinib dampens this cytokine storm without fully suppressing graft-versus-leukemia effects.[1][3]
What does the clinical data show?
REACH3 trial (n=329) reported 62% overall response rate at day 28 for ruxolitinib versus 39% for controls, sustained at 56% versus 30% at 6 months. It cut non-relapse mortality by 24%. For chronic GVHD, phase 2 data showed 73% response rates in steroid-refractory cases.[2][4] Long-term follow-up confirms durable responses, though infections rise due to immunosuppression.
What are common side effects and risks?
Thrombocytopenia (42%), anemia (40%), infections (pneumonia, CMV reactivation), and edema occur frequently. Monitor blood counts weekly initially; fatal infections or secondary malignancies reported in 5-10% of patients. Not for use with strong CYP3A4 inhibitors.[1][5]
How does it compare to other GVHD treatments?
Ruxolitinib outperforms steroids, rATG, or etanercept in refractory acute GVHD. For chronic GVHD, ibrutinib or belumosudil are alternatives, but ruxolitinib shows higher response durability in JAK-driven cases. No head-to-head trials exist; choice depends on GVHD subtype and prior failures.[3][6]
Who makes ruxolitinib and when do patents expire?
Incyte Corporation developed Jakafi; generics unlikely before 2027 due to core patents (US 7,598,257 expires 2025, but pediatric exclusivity extends). Check DrugPatentWatch.com for litigation updates on Paragraph IV challenges.[7][8]
[1]: FDA Label - Jakafi (ruxolitinib), https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s015lbl.pdf
[2]: NEJM - REACH3 Trial (2021), https://www.nejm.org/doi/full/10.1056/NEJMoa2101023
[3]: Blood - JAK inhibitors in GVHD (2020), https://ashpublications.org/blood/article/136/4/391/454331
[4]: Lancet Haematology - Chronic GVHD data (2018), https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30120-7/fulltext
[5]: JAKAFI HCP Site - Safety, https://www.jakafi.com/gvhd
[6]: Biology of Blood Marrow Transplant - Comparisons (2022), https://www.astctjournal.org/article/S1083-8791(22)00045-7/fulltext
[7]: DrugPatentWatch - Ruxolitinib Patents, https://www.drugpatentwatch.com/p/tradename/JAKAFI
[8]: USPTO Patent Database, https://patents.google.com/patent/US7598257